March 4, 2011
NOTE: Several fact sheets describe drugs that are being tested against HIV:
These drugs have not been approved by the Food and Drug Administration (FDA) for use against HIV.
Elvitegravir (also known as Gilead 9137 and JTK-303) is now in a phase III study. The drug is used boosted with ritonavir or with Gilead's new booster GS 9350. It is eliminated almost entirely via the feces, not the kidneys, so no dose adjustments are needed for patients with kidney problems.
Dolutegravir (S/GSK1349572) by ViiV Healthcare is an integrase inhibitor. Results from Phase II trials showed better results with twice-daily dosing compared to once-daily. It is going into Phase III trials. It does not require boosting.
S/GSK 1265744 by ViiV Healthcare is an integrase inhibitor. It is in a Phase IIa trial.
Scientists believe that the nucleocapsid core cannot mutate very easily, so a drug that works against zinc fingers might be effective for a long time. Unfortunately, zinc fingers are not only used by the HIV virus. Drugs that attack them could have serious side effects.
One zinc finger inhibitor -- azodicarbonamide (ADA) -- has been tested in a Phase I/II trial, but there are no recent reports on its development.
SB-728-T by Sangamo BioSciences is a zinc finger gene therapy. It started Phase I clinical trials in 2009.
KP1461 by Koronis Pharmaceuticals development was discontinued in 2008 but was reinstated following positive results from a Phase 2a clinical trial.
Bevirimat (PA457) by Myriad Genetics
BI201 by BioInvent
L870810 (integrase inhibitor) by Merck
S-1360, GW810781 (integrase inhibitor) by Shionogi and GlaxoSmithKline
Vivecon (MPC9055) by Myriad Genetics